Background: Poor growth of a foetus during pregnancy is referred to as intrauterine growth restriction (IUGR), also known as intrauterine growth retardation. There are several potential reasons, but inadequate maternal nutrition or insufficient oxygen delivery to the foetus are the most frequent ones.
The purpose of the work is to determine how sildenafil citrate affects newborn outcomes such as birth weight and admission to the neonatal intensive care unit (NICU).
Patients and Methods: A total of 120 pregnant women between the ages of 28 and 30 who were attending antenatal care clinics or being admitted to the obstetrics and gynaecology department and had FGR,defined as a lag of two weeks or more between the current biometric measurements and the documented pregnancy dating to the first trimester and anestimated foetal weight less than the 10th percentile for gestational age, were included in this randomised controlled trial study.
Results: In comparison to 40.0% and 73.3% in the control group, 21.7% of neonates in the sildenafil group have an APGAR5 score 7 and 48.3% of them are admitted to the NICU, a significant difference between the two groups(p=0.030 &0.005, respectively). In the sildenafil group, sildenafil reduced the relative risk of both by 0.62&0.60.
Conclusion: One of the biggest problems in maternity care today, as well as one of the leading causes of perinatal morbidity and death, is intrauterine growth restriction (IUGR). notwithstanding the significant strain it places on maternity and paediatric healthcare. We are still looking for a cure that will last forever. In the current study, it was discovered that sildenafil increases gestational age, prolongs pregnancy,improves birth weight, lowers the incidence of CS, and lessens IUGR-related problems.